Login / Signup

Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC.

Maria GemelliAdriana AlbiniGianpiero CatalanoMatteo IncarboneMaria CannoneEmanuela BalladoreRiccardo RicottaGiuseppe Pelosi
Published in: Expert review of anticancer therapy (2024)
Our expert opinion encapsulates the critical importance of understanding resistance mechanisms in the context of ALK inhibitors for shaping successful treatment approaches. With a focus on molecular testing and comprehensive assessment, this review contributes valuable insights to the evolving landscape of NSCLC therapy.
Keyphrases
  • advanced non small cell lung cancer
  • small cell lung cancer
  • epidermal growth factor receptor
  • single cell
  • tyrosine kinase
  • cell therapy